This was the stock's second consecutive day of losses.

Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region ...

Corporation announced further advancements in its ongoing strategy to bring translational discoveries to patient care by ...

Shares of Bio-Techne Corp. TECH slipped 1.78% to $59.98 Tuesday, on what proved to be an all-around favorable trading session ...

Proficio Capital Partners LLC increased its position in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 13.6% in the 4th quarter, according to its most recent disclosure with the SEC. The ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ...

Dr. Gregory Bean, Associate Professor of Pathology at Stanford University, will describe the direct detection of mRNA from CRTC1/3::MAML2 translocations, as alternatives to MAML2 FISH, in the ...

A month has gone by since the last earnings report for Techne (TECH). Shares have lost about 15.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...

Argus analyst David Toung lowered the firm’s price target on Bio-Techne (TECH) to $90 from $95 and keeps a Buy rating on the shares after its ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed ...